[A19-88] Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.01.2020
Project no.:
A19-88
Commission:
Commission awarded on 15.10.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Maintenance treatment of platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum-based chemotherapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-16 | Niraparib (ovarian cancer) - Addendum to Commission A19-88 | Commission completed |
| G17-15 | Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A20-98 | Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-17 | Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.